• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Medical Devices

  • Print
  • Share
  • E-mail

STAARVISC™ Sodium Hyaluronate - P000046

This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.

Product Name: STAARVISC™ Sodium Hyaluronate
Manufacturer:  Anika Therapeutics, Inc.
Address: 236 West Cummings Park, Woburn, MA 01801
Approval Date:  April 18, 2001
Approval Letter: http://www.accessdata.fda.gov/cdrh_docs/pdf/p000046a.pdf

What is it?  Sodium hyaluronate is a thick liquid similar to the natural fluid found in the eye.

How does it work?  It acts as a tissue lubricant, and also maintains the volume of eye fluid during surgery on the inside of the eye.

When is it used?  During surgery in the eye, such as: 

  • cataract removal
  • implanting intraocular lenses (IOL) 
  • corneal transplantation 
  • glaucoma-filtering surgery 
  • retinal reattachment

What will it accomplish?   It helps keep the eye’s shape and protects different tissues within the eye during surgery.

When should it not be used?  There are no known reasons that would cause this product to be dangerous if used as the company recommends. For more information on precautions, please refer to the link to the labeling below.

Additional information: The SSED and Labeling is available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p000046